NYSE:RCUS

Arcus Biosciences (RCUS) Stock Forecast, Price & News

$18.75

-0.45 (-2.34%)

(As of 09/27/2023 ET)

Compare

Today's Range: $18.51
▼
$19.35
50-Day Range: $17.62
▼
$23.04
52-Week Range: $15.70
▼
$36.13

Volume: 571,436 shs
Average Volume: 999,003 shs
Market Capitalization: $1.40 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $44.00

Arcus Biosciences MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.89 Rating Score
Upside/Downside: 134.7% Upside
$44.00 Price Target
Short Interest: Healthy
13.62% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.05
Based on 4 Articles This Week
Insider Trading: Acquiring Shares
$19.45 M Bought Last Quarter
Proj. Earnings Growth: Growing
From ($4.33) to ($3.10) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.61 out of 5 stars

Medical Sector

124th out of 976 stocks

Biotechnology Industry

3rd out of 21 stocks

4.4

Analyst's Opinion

Consensus Rating
Arcus Biosciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.89, and is based on 8 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $44.00, Arcus Biosciences has a forecasted upside of 134.7% from its current price of $18.75.
Amount of Analyst Coverage
Arcus Biosciences has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

3.0

Short Interest

Percentage of Shares Shorted
13.62% of the float of Arcus Biosciences has been sold short.
Short Interest Ratio / Days to Cover
Arcus Biosciences has a short interest ratio ("days to cover") of 8.
Change versus previous month
Short interest in Arcus Biosciences has recently decreased by 11.04%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Arcus Biosciences does not currently pay a dividend.
Dividend Growth
Arcus Biosciences does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for RCUS.

1.7

News and Social Media Coverage

News Sentiment
Arcus Biosciences has a news sentiment score of 0.05. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.71 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 4 news articles for Arcus Biosciences this week, compared to 3 articles on an average week.
Search Interest
Only 3 people have searched for RCUS on MarketBeat in the last 30 days. This is a decrease of -63% compared to the previous 30 days.
MarketBeat Follows
Only 1 people have added Arcus Biosciences to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

4.2

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Arcus Biosciences insiders have bought 1,331.19% more of their company's stock than they have sold. Specifically, they have bought $19,452,600.00 in company stock and sold $1,359,194.00 in company stock.
Percentage Held by Insiders
13.80% of the stock of Arcus Biosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
74.67% of the stock of Arcus Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Arcus Biosciences are expected to grow in the coming year, from ($4.33) to ($3.10) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Arcus Biosciences is -4.73, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Arcus Biosciences is -4.73, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Arcus Biosciences has a P/B Ratio of 2.07. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Arcus Biosciences (NYSE:RCUS) Stock

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT investigational monoclonal antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies. It also develops Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in Phase 2 clinical trial; Quemliclustat, a small-molecule CD73 inhibitor, which is Phase 1b and Phase 2 clinical trial; Zimberelimab, an anti-PD-1 antibody, which is in Phase 2 clinical trial for metastatic cell lung cancer and monotherapy; and AB521, an oral and small-molecule inhibitor of HIF-2a, which is in Phase 1 clinical trial for the treatment of Von Hippel-Lindau disease. In addition, the company's preclinical pipeline products include AB598, a CD39 antibody; and AB801, a small molecule Axl inhibitor. It has a clinical collaboration with AstraZeneca to evaluate domvanalimab in combination with durvalumab in a registrational phase 3 clinical trial in patients with unresectable Stage 3 NSCLC; and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is headquartered in Hayward, California.

RCUS Price History

30 days | 90 days | 365 days | Advanced Chart

RCUS Stock News Headlines

September 27, 2023 | finance.yahoo.com

Precision BioSciences Receives U.S. Patent Allowance Covering PBGENE-PMM for m.3243-Associated Mitochondrial Diseases

September 24, 2023 | fool.com

Arcus Biosciences (NYSE: RCUS)

September 28, 2023 | Altimetry (Ad)

Advisor to FBI: Sell META now

Stocks just keep going up. But all isn’t what it seems, according to an FBI and Pentagon advisor. Find out what he knows, here.

September 19, 2023 | markets.businessinsider.com

Truist Financial Remains a Buy on Arcus Biosciences (RCUS)

September 7, 2023 | msn.com

Truist Securities Reiterates Arcus Biosciences (RCUS) Buy Recommendation

September 5, 2023 | finance.yahoo.com

Arcus Biosciences (RCUS): A Modestly Undervalued Gem?

September 5, 2023 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Sanofi (OtherSNYNF), Neurocrine (NBIX) and Arcus Biosciences (RCUS)

August 24, 2023 | markets.businessinsider.com

5 Analysts Have This to Say About Arcus Biosciences

September 28, 2023 | Behind the Markets (Ad)

66,000% upside on tiny biotech?

The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.

August 24, 2023 | msn.com

Mizuho Reiterates Arcus Biosciences (RCUS) Buy Recommendation

August 23, 2023 | msn.com

Gilead, Arcus, iTeos, other biopharmas get boost from accidental disclosure of Roche lung cancer trial data

August 23, 2023 | finance.yahoo.com

Arcus Biosciences to Participate in Multiple Upcoming Investor Conferences

August 23, 2023 | finance.yahoo.com

Arcus Biosciences: A Modestly Undervalued Opportunity?

August 23, 2023 | markets.businessinsider.com

Arcus Biosciences (RCUS) Receives a Buy from Mizuho Securities

August 17, 2023 | msn.com

HC Wainwright & Co. Maintains Precision Biosciences (DTIL) Buy Recommendation

August 17, 2023 | msn.com

What Is Precision BioSciences CAR T Pipeline Value? Analyst Lowers Price Target To Justify Valuation

August 7, 2023 | markets.businessinsider.com

Arcus Biosciences, Inc Q2 Loss increases, but beats estimates

August 7, 2023 | msn.com

Arcus Biosciences GAAP EPS of -$1.04, revenue of $29M

August 7, 2023 | finance.yahoo.com

Arcus Biosciences Reports Second-Quarter 2023 Financial Results and Provides a Pipeline Update

August 4, 2023 | finance.yahoo.com

Precision BioSciences Reports Second Quarter 2023 Financial Results and Provides Business Update

August 4, 2023 | benzinga.com

Preview: Arcus Biosciences's Earnings

July 27, 2023 | markets.businessinsider.com

Mizuho Securities Keeps Their Buy Rating on Arcus Biosciences (RCUS)

July 12, 2023 | benzinga.com

Cantor Fitzgerald Reinstates Overweight on Arcus Biosciences, Maintains $46 Price Target

July 12, 2023 | msn.com

Cantor Fitzgerald Reiterates Arcus Biosciences (RCUS) Overweight Recommendation

July 9, 2023 | seekingalpha.com

Acumen, BridgeBio, Arcus among BTIG's top healthcare picks for 2H 2023

July 6, 2023 | benzinga.com

Arcus Biosciences 13D Filing Shows Gilead Sciences, Inc. Increased Stake In Co To 35%

June 15, 2023 | msn.com

Arcus Biosciences: Gilead Partnered TIGIT Pioneer Excites But Frustrates

See More Headlines

Receive RCUS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Arcus Biosciences and its competitors with MarketBeat's FREE daily newsletter.

RCUS Company Calendar

Last Earnings: 8/07/2023
Today: 9/28/2023
Next Earnings (Estimated): 11/01/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NYSE
Industry: Biotechnology
Sub-Industry: N/A
Sector: Medical
Current Symbol: NYSE:RCUS
CUSIP: N/A
CIK: 1724521
Web: www.arcusbio.com
Phone: (510) 694-6200
Fax: N/A
Employees: 500
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $44.00
High Stock Price Forecast: $70.00
Low Stock Price Forecast: $23.00
Forecasted Upside/Downside: +134.7%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.89
Research Coverage: 9 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($3.96)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-267,000,000.00
Net Margins: -235.99%
Pretax Margin: -233.59%
Return on Equity: -45.51%
Return on Assets: -22.02%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 5.48
Quick Ratio: 5.48

Sales & Book Value

Annual Sales: $112 million
Price / Sales: 12.47
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $9.07 per share
Price / Book: 2.07

Miscellaneous

Outstanding Shares: 74,500,000
Free Float: 64,222,000
Market Cap: $1.40 billion
Optionable: Optionable
Beta: 0.82

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for October 2023. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

Dr. Terry J. Rosen Ph.D. (Age 63)
Co-Founder, Chairman & CEO
Comp: $756.11k

Dr. Juan Carlos Jaen Ph.D. (Age 65)
Co-Founder, Pres & Director
Comp: $931.14k

Mr. Robert C. Goeltz II (Age 50)
Principal Financial Officer & CFO
Comp: $745.29k

Ms. Jennifer A. Jarrett M.B.A. (Age 52)
COO & Director
Comp: $925.29k

Dr. Dimitry S.A. Nuyten M.D. (Age 47)
Ph.D., Chief Medical Officer
Comp: $700.34k

Dr. K. Christopher Garcia Ph.D.
Co-Founder & Member of Scientific Advisory Board

Mr. Alexander Azoy (Age 47)
VP of Fin. & Principal Accounting Officer

Dr. Stephen Young Ph.D. (Age 54)
Sr. VP of Technology & Quantitative Biology

Dr. Jonathan Yingling Ph.D. (Age 54)
Chief Scientific Officer

Ms. Katherine Bock
VP of Investor Relations & Corp. Strategy

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

RCUS Stock - Frequently Asked Questions

Should I buy or sell Arcus Biosciences stock right now?: 9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Arcus Biosciences in the last twelve months. There are currently 1 hold rating and 8 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" RCUS shares.
View RCUS analyst ratings or view top-rated stocks.
What is Arcus Biosciences' stock price forecast for 2023?: 9 Wall Street analysts have issued 1 year target prices for Arcus Biosciences' stock. Their RCUS share price forecasts range from $23.00 to $70.00. On average, they expect the company's share price to reach $44.00 in the next year. This suggests a possible upside of 134.7% from the stock's current price.
View analysts price targets for RCUS or view top-rated stocks among Wall Street analysts.
How have RCUS shares performed in 2023?: Arcus Biosciences' stock was trading at $20.68 on January 1st, 2023. Since then, RCUS stock has decreased by 9.3% and is now trading at $18.75.
View the best growth stocks for 2023 here.
When is Arcus Biosciences' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 1st 2023.
View our RCUS earnings forecast.
How were Arcus Biosciences' earnings last quarter?: Arcus Biosciences, Inc. (NYSE:RCUS) announced its earnings results on Monday, August, 7th. The company reported ($1.04) EPS for the quarter, beating analysts' consensus estimates of ($1.10) by $0.06. The business earned $29 million during the quarter, compared to analyst estimates of $31.81 million. Arcus Biosciences had a negative net margin of 235.99% and a negative trailing twelve-month return on equity of 45.51%. Arcus Biosciences's revenue for the quarter was up 7.4% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.93) earnings per share.
What ETFs hold Arcus Biosciences' stock?: ETFs with the largest weight of Arcus Biosciences (NYSE:RCUS) stock in their portfolio include iShares Genomics Immunology and Healthcare ETF (IDNA), Range Cancer Therapeutics ETF (CNCR), ALPS Medical Breakthroughs ETF (SBIO) and Invesco S&P SmallCap Health Care ETF (PSCH).Virtus LifeSci Biotech Clinical Trials ETF (BBC).
What is Terry Rosen, Ph.D.'s approval rating as Arcus Biosciences' CEO?: 4 employees have rated Arcus Biosciences Chief Executive Officer Terry Rosen, Ph.D. on Glassdoor.com. Terry Rosen, Ph.D. has an approval rating of 100% among the company's employees. This puts Terry Rosen, Ph.D. in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.
What other stocks do shareholders of Arcus Biosciences own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Arcus Biosciences investors own include Horizon Therapeutics Public (HZNP), BioDelivery Sciences International (BDSI), Pfizer (PFE), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), CRISPR Therapeutics (CRSP), Gilead Sciences (GILD), Inovio Pharmaceuticals (INO), Agile Therapeutics (AGRX) and Advanced Micro Devices (AMD).

When did Arcus Biosciences IPO?: (RCUS) raised $99 million in an initial public offering on Thursday, March 15th 2018. The company issued 7,100,000 shares at $13.00-$15.00 per share. Citigroup, Goldman Sachs and Leerink Partners acted as the underwriters for the IPO.
What is Arcus Biosciences' stock symbol?: Arcus Biosciences trades on the New York Stock Exchange (NYSE) under the ticker symbol "RCUS."
Who are Arcus Biosciences' major shareholders?: Arcus Biosciences' stock is owned by many different retail and institutional investors. Top institutional investors include BlackRock Inc. (12.71%), State Street Corp (5.83%), Boxer Capital LLC (2.15%), Dimensional Fund Advisors LP (1.56%), Alliancebernstein L.P. (1.40%) and Geode Capital Management LLC (1.38%). Insiders that own company stock include Alexander Azoy, Carolyn C Tang, Carolyn C Tang, Gilead Sciences Inc, Gilead Sciences, Inc, Jennifer Jarrett, Juan C Jaen, Kathryn E Falberg, Robert C Goeltz II, Terry J Rosen, William Grossman and Yasunori Kaneko.
View institutional ownership trends.
How do I buy shares of Arcus Biosciences?: Shares of RCUS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Arcus Biosciences' stock price today?: One share of RCUS stock can currently be purchased for approximately $18.75.
How much money does Arcus Biosciences make?: Arcus Biosciences (NYSE:RCUS) has a market capitalization of $1.40 billion and generates $112 million in revenue each year. The company earns $-267,000,000.00 in net income (profit) each year or ($3.96) on an earnings per share basis.
How many employees does Arcus Biosciences have?: The company employs 500 workers across the globe.
How can I contact Arcus Biosciences?: Arcus Biosciences' mailing address is 3928 Point Eden Way, Hayward CA, 94545. The official website for the company is www.arcusbio.com. The company can be reached via phone at (510) 694-6200 or via email at investorinfo@arcusbio.com.

This page (NYSE:RCUS) was last updated on 9/28/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial